• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受持续性非卧床腹膜透析患者的血浆草酸盐水平

Plasma oxalate in patients receiving continuous ambulatory peritoneal dialysis.

作者信息

Tomson C R, Channon S M, Parkinson I S, Owen J P, Ward M K, Simpson J M, Laker M F

机构信息

Department of Medicine, Medical School, University of Newcastle upon Tyne, UK.

出版信息

Nephrol Dial Transplant. 1988;3(3):295-9.

PMID:3140104
Abstract

Plasma oxalate has been measured in 125 patients maintained on continuous ambulatory peritoneal dialysis using an enzyme/bioluminescent assay. Values ranged between 6 and 134 mumol/l, with a positively skewed distribution. Multiple linear regression analysis with plasma oxalate as the dependent variable showed highly significant associations with the dose of ascorbic acid, dose of alfacalcidol, and plasma creatinine, and weaker associations with serum phosphate, serum calcium, and body weight. When the presence of other potential risk factors was taken into account, no significant relationship could be found between the presence of clinically evident cardiac or vascular disease and plasma oxalate.

摘要

采用酶促/生物发光分析法,对125例持续非卧床腹膜透析患者的血浆草酸盐进行了测定。其值在6至134μmol/L之间,呈正偏态分布。以血浆草酸盐作为因变量的多元线性回归分析显示,其与抗坏血酸剂量、阿法骨化醇剂量和血浆肌酐高度相关,与血清磷酸盐、血清钙和体重的相关性较弱。当考虑其他潜在风险因素的存在时,未发现临床明显的心脏或血管疾病与血浆草酸盐之间存在显著关系。

相似文献

1
Plasma oxalate in patients receiving continuous ambulatory peritoneal dialysis.接受持续性非卧床腹膜透析患者的血浆草酸盐水平
Nephrol Dial Transplant. 1988;3(3):295-9.
2
Plasma concentration and peritoneal clearance of oxalate in patients on continuous ambulatory peritoneal dialysis (CAPD).持续性非卧床腹膜透析(CAPD)患者中草酸盐的血浆浓度及腹膜清除率
Clin Nephrol. 1986 Apr;25(4):181-5.
3
Plasma oxalate concentration, oxalate clearance and cardiac function in patients receiving haemodialysis.
Nephrol Dial Transplant. 1989;4(9):792-9.
4
Determination of serum oxalate using peroxyoxalate chemiluminescence of free oxalic acid.
J Biolumin Chemilumin. 1993 Jan-Feb;8(1):21-4. doi: 10.1002/bio.1170080105.
5
Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients.规律血液透析患者补充维生素C所致继发性高草酸血症
Clin Nephrol. 1986 Nov;26(5):239-43.
6
Plasma oxalate in patients with chronic renal failure receiving continuous ambulatory peritoneal dialysis or hemodialysis.接受持续性非卧床腹膜透析或血液透析的慢性肾衰竭患者的血浆草酸盐水平
Am J Kidney Dis. 1991 Oct;18(4):441-5. doi: 10.1016/s0272-6386(12)80111-9.
7
Effects of ascorbic acid and pyridoxine supplementation on oxalate metabolism in peritoneal dialysis patients.补充抗坏血酸和吡哆醇对腹膜透析患者草酸代谢的影响。
Am J Kidney Dis. 1992 Jul;20(1):42-9. doi: 10.1016/s0272-6386(12)80315-5.
8
Oxalate retention in chronic renal failure: tubular vs glomerular diseases.
Clin Nephrol. 1989 Aug;32(2):87-95.
9
Oxalate metabolism in end-stage renal disease: the effect of ascorbic acid and pyridoxine.终末期肾病中的草酸盐代谢:抗坏血酸和吡哆醇的作用。
Nephrol Dial Transplant. 1988;3(1):28-32.
10
Effect of pyridoxine supplementation on plasma oxalate concentrations in patients receiving dialysis.补充吡哆醇对接受透析患者血浆草酸盐浓度的影响。
Eur J Clin Invest. 1989 Apr;19(2):201-5. doi: 10.1111/j.1365-2362.1989.tb00218.x.